Comparison of genome segments 2, 7 and 10 of bluetongue viruses serotype 2 for differentiation between field isolates and the vaccine strain

Bréard, Emmanuel; Sailleau, Corinne; Coupier, Hervé; Mure-Ravaud, Karine; Hammoumi, Saliha; Gicquel, Bernard; Hamblin, C.; Dubourget, P; Zientara, Stéphan

doi:10.1051/vetres:2003036

Cited by 31 publications

(20 citation statements)

References 26 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serologic results provided supportive evidence of a recent dengue infection i.e., presence of immunoglobulin M, as determined by antibody-capture enzyme immunoassay, and immunoglobulin G seroconversion by 90% plaque reduction neutralization test on Vero cells (4). As shown in the Table, dengue virus serotype 3 was identifi ed, and antibody results were negative for 3 other fl aviviruses.…”

Section: Indigenous Denguementioning

confidence: 81%

Bluetongue in Eurasian Lynx

Jauniaux¹,

Clercq²,

Cassart³

et al. 2008

Emerg. Infect. Dis.

View full text Add to dashboard Cite

Section: Indigenous Denguementioning

confidence: 81%

Bluetongue in Eurasian Lynx

Jauniaux¹,

Clercq²,

Cassart³

et al. 2008

Emerg. Infect. Dis.

View full text Add to dashboard Cite

“…Furthermore, many current diagnostic tests cannot distinguish between an individual who is naturally infected and an individual that received a modified live vaccine. [52][53][54] Effectiveness of live vaccines also requires that they be properly handled before administration. Keeping attenuated vaccines viable (i.e., proper storage) has been problematic in worldwide efforts to eradicate polio.…”

Section: Live Vaccinesmentioning

confidence: 99%

Vaccine adjuvants: Current challenges and future approaches

Wilson-Welder

Torres

Kipper

et al. 2009

Journal of Pharmaceutical Sciences

234

176

View full text Add to dashboard Cite

For humans, companion animals, and food producing animals, vaccination has been touted as the most successful medical intervention for the prevention of disease in the twentieth century. However, vaccination is not without problems. With the development of new and less reactogenic vaccine antigens, which take advantage of molecular recombinant technologies, also comes the need for more effective adjuvants that will facilitate the induction of adaptive immune responses. Furthermore, current vaccine adjuvants are successful at generating humoral or antibody mediated protection but many diseases currently plaguing humans and animals, such as tuberculosis and malaria, require cell mediated immunity for adequate protection. A comprehensive discussion is presented of current vaccine adjuvants, their effects on the induction of immune responses, and vaccine adjuvants that have shown promise in recent literature.

show abstract

“…1). Between 1998 and 2004, when there were incursions of BTV into the Mediterranean Basin, the Balkans and beyond (Table I), the disease penetrated into areas where C. imicola does not occur, thus incriminating novel vectors (3,8,12,42,62,64,119). This was confirmed subsequently when the causative virus was isolated from mixed pools of the two species Culicoides obsoletus (Meigen) and Culicoides scoticus (Downes and Kettle) collected in central Italy (92,93) and from Culicoides pulicaris (Linnaeus) in Sicily (11).…”

Section: Emergency Situationsmentioning

confidence: 99%

“…This procedure has been used successfully for bluetongue in the Mediterranean endemic area (8,21,39,119). The vaccination strategy was mainly based on the use of the monovalent or polyvalent attenuated vaccines produced by Onderstepoort Biological Products Ltd (South Africa) and to a lesser extent on the inactivated vaccine produced by Mérial SAS in Lyons, France (8,39,119). Each of these points is described in more detail below.…”

Section: Regulatory Issues Surrounding the Temporary Authorisation Ofmentioning

confidence: 99%

“…In this case, the vaccination programme must be promptly adapted (119). If possible, an RT-PCR test should be carried out to differentiate between the wild type and vaccine viruses (8). In addition, strain genotyping permits the study of the molecular epidemiology of BT and the monitoring of possible reassortment of genome segments between vaccine and field viruses (7).…”

Section: Monitoring Analysis and Possible Adjustment Of Field Vaccinmentioning

confidence: 99%

See 1 more Smart Citation

Regulatory issues surrounding the temporary authorisation of animal vaccination in emergency situations: the example of bluetongue in Europe

Saegerman¹,

Hubaux²,

Urbain³

et al. 2007

Rev. Sci. Tech. OIE

View full text Add to dashboard Cite

SummaryA marketing authorisation for a veterinary vaccine is granted after the quality, safety and efficacy of the product have been assessed in accordance with legal standards. The assessment includes complete characterisation and identification of seed material and ingredients, laboratory and host animal safety and efficacy studies, stability studies, and post-licensing monitoring of field performance. This assessment may not be possible during the emergence of a new animal disease, but several mechanisms exist to allow for the availability of products in an emergency animal health situation, e.g. autogenous biologics, conditional licences, experimental and emergency use authorisations, the importation of products in use elsewhere in the world and pre-approved vaccine banks. Using the emergence of bluetongue in northern Europe as an example, the regulatory issues regarding the temporary authorisation of animal vaccination are described. Several conditions must be fulfilled before a temporary authorisation can be granted, e.g. inactivated vaccines should be used in order to exclude reversion to virulence and reassortment between vaccine viruses and/or field strains of the bluetongue virus; decision-making must be supported by scientific evidence and risk analysis; there must be a complete census of the susceptible animals that were vaccinated; vaccination protocols must be adhered to and there must be a scheme allowing for registration, delivery and follow-up of vaccination, and monitoring, analysis and, possibly, adjustment of field use of the vaccination. This temporary authorisation must be replaced by a full authorisation as quickly as possible.

show abstract

Comparison of genome segments 2, 7 and 10 of bluetongue viruses serotype 2 for differentiation between field isolates and the vaccine strain

Abstract: -Bluetongue (BT) virus serotype 2 (BTV 2)

Cited by 31 publications

References 26 publications

Bluetongue in Eurasian Lynx

Bluetongue in Eurasian Lynx

Vaccine adjuvants: Current challenges and future approaches

Regulatory issues surrounding the temporary authorisation of animal vaccination in emergency situations: the example of bluetongue in Europe

Contact Info

Product

Resources

About